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ABSTRACT  
This study is the first pharmacological characterization of the novel chemical entity, ORM-
3819 (L-6-{4-[N’-(4-Hydroxi-3-methoxy-2-nitro-benzylidene)-hydrazino]-phenyl}-5-methyl-
4,5-dihydro-2H-pyridazin-3-one), focusing primarily on its cardiotonic effects. ORM-3819 
binding to cardiac Troponin C (cTnC) was confirmed by nuclear magnetic resonance 
spectroscopy, and a selective inhibition of the phosphodiesterase III (PDE III) isozyme (IC50 
= 3.88 ± 0.3 nM) was revealed during in vitro enzyme assays. The Ca
2+
-sensitizing effect of 
ORM-3819 was demonstrated in vitro in permeabilized myocyte-sized preparations from left 
ventricles (LV) of guinea pig hearts (ΔpCa50 = 0.12 ± 0.01; EC50 = 2.88 ± 0.14 µM). ORM-
3819 increased the maximal rate of LV pressure development (+dP/dtmax) (EC50 = 8.9 ± 1.7 
nM) and LV systolic pressure (EC50 = 7.63 ± 1.74 nM) in Langendorff-perfused guinea pig 
hearts. Intravenous administration of ORM-3819 increased LV +dP/dtmax (EC50 = 0.13 ± 0.05 
µM/kg) and improved the rate of LV pressure decrease (-dP/dtmax); (EC50 = 0.03 ± 0.02 
µM/kg) in healthy guinea pigs. In an in vivo dog model of myocardial stunning, ORM-3819 
restored the depressed LV +dP/dtmax and improved % segmental shortening (%SS) in the 
ischaemic area (to 18.8 ± 3), which was reduced after the ischaemia-reperfusion insult (from 
24.1 ± 2.1 to 11.0 ± 2.4). Our data demonstrate ORM-3819 as a potent positive inotropic 
agent exerting its cardiotonic effect by a cTnC-dependent Ca
2+
-sensitizing mechanism in 
combination with the selective inhibition of the PDE III isozyme. This dual mechanism of 
action results in the concentration-dependent augmentation of the contractile performance 
under control conditions and in the postischaemic failing myocardium. 
 
Keywords: ORM-3819; levosimendan; Ca
2+
 sensitization; phosphodiesterase III inhibition; 
positive inotropic agent; myocardial stunning 
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Abbrevation’s list 
Ca
2+
: calcium ion 
[Ca
2+
]: calcium ion concentration 
cTnC: cardiac troponin C 
cTnCcs: recombinant chicken cTnC with mutation of cysteine-35 to serine 
DMSO: dimethyl-sulfoxide 
DTT: dithiothreitol  
Factive: active force 
Fpassive: passive force 
Fmax: maximum force level 
Ftotal: total force level 
HSQC: heteronuclear single-quantum coherence  
LAD: anterior descending branch of the left coronary artery  
LCX: circumflex branch of the left coronary artery 
LV: left ventricle 
nHill: Hill coefficient 
NOE: nuclear Overhauser-effect 
NOESY: nuclear Overhauser-effect spectroscopy  
NMR: nuclear magnetic resonance 
pCa: -log of calcium ion concentration 
pCa50: -log of calcium ion concentration at half-maximal isometric force production 
PDE: phosphodiesterase  
+dP/dtmax: peak of the first derivative of the LV pressure development 
-dP/dtmin: maximal rate of LV pressure decrease 
%SS: percent segment shortening 
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1. INTRODUCTION  
Different pharmacological approaches of positive inotropy have been considered for 
compensation of the weakened cardiac contractions in heart failure. Traditional inotropes 
mobilize intracellular calcium ions (Ca
2+
) in cardiomyocytes to improve the contractility of 
the left ventricle (LV) while increasing the myocardial oxygen consumption, heart rate and 
the risk for arrhythmias (Endoh, 2001). LV performance can be also supported by Ca
2+
 
sensitizers, designed to tune the Ca
2+
-dependence of force production via targeting directly 
the contractile protein machinery, theoretically without direct interference with the Ca
2+
 
homeostasis (Nagy et al., 2014).  
The interaction between Ca
2+
 and cardiac troponin C (cTnC) plays a central role in the 
myocardial contractile regulation. Contraction is induced by a conformational change of cTnC 
triggered by its Ca
2+
 binding, allowing myosin to interact with actin filaments, leading 
ultimately to force production and cardiomyocyte shortening (Gomes et al., 2002). Drug 
molecules promoting cTnC function may improve the contractility of the failing heart (Endoh, 
2001). Levosimendan, the (-)-enantiomer of {[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-
pyridazinyl)phenyl]hydrazono}propanedinitrile was discovered during Ca
2+
-dependent 
affinity chromatography in the presence of cTnC (Haikala et al., 1995). Subsequent 
investigations revealed its binding to a hydrophobic patch formed in the regulatory domain of 
cTnC following a Ca
2+
-induced conformational change (Ovaska and Taskinen, 1991; 
Pollesello et al., 1994). Levosimendan was shown to interact with the Ca
2+
-bound cTnC close 
to its D/E linker domain of the N-terminal region (Sorsa et al., 2001; Robertson et al., 2010), 
thereby stabilizing the open conformation of the Ca
2+
 – cTnC complex. 
Based on structure to activity relationships of known Ca
2+
 sensitizers, novel inotropes 
possessing selective Ca
2+
-dependent binding to cTnC and fast pharmacokinetics in vivo are 
constantly looked for (Lindert et al., 2015). In line, ORM-3819 (L-6-{4-[N’-(4-Hydroxi-3-
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methoxy-2-nitro-benzylidene)-hydrazino]-phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-
one) was designed as a new chemical entity following in silico drug discovery developments 
(Fig. 1A). 
Until now not a single Ca
2+
-sensitizing agent reached the clinical arena as a “pure” 
Ca
2+
 sensitizer and additional cardiovascular effects through independent drug targets have 
been pinpointed. For example, levosimendan and its active metabolite, OR-1896 (the (-)-
enantiomer of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide) 
(Fig. 1B and 1C) exhibit vasodilator and cardio-protective effects due to opening ATP-
dependent potassium channels in vascular smooth muscle cells and in cardiomyocyte 
mitochondria (Kopustinskiene et al., 2001; Lepran et al., 2006; Godeny et al., 2013). The 
vascular effects of levosimendan and OR-1896 can be effectively antagonized by selective 
potassium channel blockers (Pataricza et al., 2003; Hohn et al., 2004). Moreover, highly 
selective phosphodiesterase III (PDE III) inhibitory potentials were also reported for the 
above compounds (Szilagyi et al., 2004).  
ORM-3819 could have a different pattern of action in comparison with previous 
inotropes, deriving from its binding to cTnC and inhibition of PDE isozymes. Hereby we 
report on the pharmacological characterization of ORM-3819 through a wide range of in 
vitro, ex vivo and in vivo studies. To these ends, (1) first we confirmed the binding of ORM-
3819 to cTnC, then we evaluated its (2) positive inotropic effects in permeabilized myocyte-
sized preparations and in working heart models of non-failing and failing hearts and we also 
highlighted its (3) phosphodiesterase inhibitor effects. 
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2. MATERIAL AND METHODS 
 
2.1. Binding of ORM-3819 to cardiac troponin C 
2.1.1. Protein samples 
Recombinant chicken cTnC with mutation of cysteine-35 to serine (cTnCcs) was used 
throughout this study. In structural and binding studies, the presence of cysteine-84 of cTnC 
in its reduced state was considered to be critical for ORM-3819 binding (similarly to that for 
levosimendan). Therefore, mutant cTnCs (Cys-35 to Ser) were employed to prevent disulfide 
formation between cysteine-35 and cysteine-84 (Sorsa et al., 2001). The expression and 
purification of the unlabelled, 
15
N-, and 
15
N/
13
C-labelled cTnCcs were achieved as described 
elsewhere (Finley et al., 1999). Purified cTnCcs was characterized by high performance liquid 
chromatography, mass spectometry analysis and sodium dodecylsulfate gel electrophoresis. 
Lyophilized proteins were solubilised in 20 mM Bis-Tris, 10 mM CaCl2, and 5% of D2O, 
while the pH was adjusted to 6.8 at room temperature. 1 mM dithiothreitol (DTT) was also 
added to the protein solution. All data were collected with fully Ca
2+
-loaded cTnCcs. 
2.1.2. Drug samples 
ORM-3819 was kindly provided and specifically 
13
C-labelled for the nuclear Overhauser-
effect spectroscopy (NOESY) by Orion Pharma (Espoo, Finland). The stock solutions of 
ORM-3819 were prepared by dissolving the weighted amounts of powder in deutereted 
dimethyl-sulfoxide (DMSO). Drug concentrations between 10 mM to 20 mM in stock 
solutions were used, while protected from light and stored at room temperature. Small 
amounts of DMSO neither affected the cTnCCS spectra nor the drug binding to cTnCCS (Li et 
al., 2000).  
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2.1.3. Nuclear magnetic resonance (NMR) spectroscopy 
All NMR experiments were acquired by Varian Inova 500, 600 or 800 MHz spectrometers at 
the temperature from 5 C to 40 C. In order to determine the binding site of the drug 
molecule to cTnCcs, the following NMR spectra were recorded: one-dimensional proton 
spectra (1D 
1
H spectra), 2D 
1
H-
13
C-, or 
1
H-
15
N heteronuclear single-quantum coherence 
(HSQC), and 2D 
13
C-edited 
1
H-
1
H NOESY of the selectively labelled ORM-3819, as detailed 
elsewhere (Sorsa et al., 2001). Briefly, 1D 
1
H spectra were collected to monitor the stability of 
ORM-3819 under various experimental conditions. The interaction of ORM-3819 with 
cTnCCS was initially followed by 
1
H-
15
N HSQC of cTnC, recorded at 800 MHz using 256 
time increments (ni) and 16 transients (nt) and spectral widths of 11000 Hz in proton 
dimension and 2200 Hz in nitrogen dimension in the presence and absence of ORM-3819. 
Then, the temperature behaviour of the cTnCCS/ORM-3819 complex was evaluated by 1D 
1
H-
13
C HSQC of specifically 
13
C-labelled ORM-3819 and unlabelled cTnCCS. In order to localize 
the exact binding sites of ORM-3819 in cTnCCS, 2D 
13
C-edited 
1
H-
1
H NOESY spectra of the 
cTnCCS/selectively labelled ORM-3819 complex (ni = 256, nt = 48, spectral widths for both 
dimensions 10000 Hz, 800 MHz) were acquired for the drug and protein – drug samples. The 
1
H chemical shifts were referenced to the water signal (4.62 ppm), and the 
13
C- and 
15
N-
chemical shifts were referenced indirectly relative to 3-trimethylsilyl-propionate sodium salt. 
2.2. Inhibition of phosphodiesterase (PDE) isozymes 
High purity of PDE III and PDE IV isozymes were isolated from human platelets and 
promonocytic cell line of patients with myeloid leukaemia (U-937), respectively. The 
procedures of isozyme isolation and the determination of PDE activity were reported 
elsewhere (Weishaar et al., 1986; Torphy et al., 1992). In brief, the supernatant fraction of the 
tissue homogenate was added to a diethylaminoethanol-sepharose column and then eluted 
with a linear sodium acetate gradient buffer. Collected fractions with peak PDE activities 
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were analysed for cAMP PDE activity. Purified PDE isozymes were incubated at 30 
o
C for 30 
min in a reaction mixture containing [
3
H]-cAMP (0.1 µM) and cAMP (0.1 µM) in the 
presence or in the absence of ORM-3819. The amount of [
3
H]-5’-AMP regarded as a 
degradation product was determined by using liquid scintillation detection. Milrinone (IC50 = 
0.247 µM for PDE III) and rolipram (IC50 = 0.11 µM for PDE IV) were used as reference 
compounds to verify the specificity of the PDE assay. Inhibitory assays were performed in 
duplicates. 
2.3. Determination of the cardiotonic effect of ORM-3819 
2.3.1. Chemicals 
Concentrated stock solutions of ORM-3819 (10 mM) were prepared in DMSO and then stored 
at 4 
ο
C for in vitro and ex vivo investigations. All test solutions containing ORM-3819 were 
freshly prepared on each experimental day. The final DMSO concentration of the 
experimental solutions never exceeded 0.1% in working heart studies and 1% in single-cell 
force measurements. DMSO itself did not affect the contractility of the preparations. ORM-
3819 was dissolved in isotonic saline vehicle (0.9% NaCl + NaOH q.s.) for that of in vivo 
studies. DMSO and the other chemicals were obtained from Sigma (St. Louis, USA) and 
Merck (Darmstadt, Germany). 
2.3.2. Animals 
Investigations were performed on 8 – 15-week-old male guinea pigs, weighing 250 – 500 g 
and mongrel dogs of either sex with a mean body weight of 25.2 ± 0.9 kg (ordered from Toxi-
Coop Toxicological Research Centre Zrt., Dunakeszi, Hungary; Mollegaard Breeding Center 
Ltd., Denmark and Charles River, Germany). Animals were fed a standard chow and drank 
tap water ad libitum. Animals were housed in an animal room (temperature: 10 – 20 °C; 
humidity: 40 – 70%; lightening: 12 h per day, 2 – 3 animals per pen/cages). Anaesthesia is 
detailed in the corresponding subsections of the in vitro, ex vivo and in vivo investigations. All 
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procedures employed in this work conformed strictly to Directive 2010/63/EU of the 
European Parliament and were approved by the Ethical Committee of the University of 
Debrecen (Ethical Statement number: 1/2013/DE MÁB).  
2.3.3. In vitro isometric force measurements in isolated and skinned myocyte-sized 
preparations 
Contractile force measurements were carried out in mechanically isolated and chemically 
permeabilized LV cardiomyocytes of guinea pigs, as described elsewhere (Papp et al., 2004). 
Guinea pigs were anesthetized with an intraperitoneal injection of sodium pentobarbital 
(Release, Garbsen, Germany; 150 mg/kg). Hearts were quickly excised and the LVs were 
dissected in cold isolating solution (MgCl2: 1 mM, KCl: 100 mM, EGTA: 2 mM, ATP: 4 
mM, imidazole: 10 mM; pH 7.0) and then stored in -80 
o
C. Deep-frozen myocardial tissue 
samples were defrosted, mechanically disrupted and then permeabilized by incubating for 5 
min in cold isolating solution supplemented with 0.5% Triton X-100. Isolated and 
permeabilized cardiomyocytes were then attached with silicone adhesive (DAP 100% all-
purpose silicone adhesive sealant, Baltimore, USA) between two stainless insect needle, 
connected to an electromagnetic motor (Aurora Scientific Inc., Aurora, Canada) and a 
sensitive force transducer (SensoNor, Horten, Norway). After adjustment of the sarcomere 
length to 2.3 µm, the contractile machinery was activated by transferring the cardiomyocyte 
from a relaxing to activating solution. The compositions of the activating and relaxing 
solutions were calculated as detailed elsewhere (Fabiato and Fabiato., 1979). Relaxing 
solutions contained N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (100 mM), KCl 
(37.11 mM), MgCl2 (6.41 mM), ATP (6.94 mM), creatine-phosphate (15 mM), pH 7.2. 
Additionally, activating solutions contained Ca
2+
-EGTA (7 mM). The Ca
2+
 concentrations 
([Ca
2+
]) expressed in pCa units were estimated by -lg [Ca
2+
]. The pCa of the activating and 
relaxing solutions was 4.75 and 9.0, respectively. Protease inhibitors were added to all 
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solutions: phenylmethylsulfonyl fluoride (0.5 mM), leupeptin (40 μM), E-64 (10 μM). Once 
the isometric force reached the maximum, a rapid release-restretch manoeuvre (30 ms) was 
applied to determine the baseline of the force generation and hence the Ca
2+
-activated total 
force (Ftotal). Fitting of the force re-development phase to a single exponential following the 
release-restretch manoeuvre allowed the characterization of the kinetics of the actin-myosin 
cross-bridges (rate constant of force redevelopment in the presence of saturating Ca
2+
 
concentration). Ca
2+
-independent passive force (Fpassive) of the cardiomyocytes was then 
measured by shortening to 80% of the original preparation length at pCa 9.0 for 8 sec. The 
active force (Factive) was calculated as a difference of the Ftotal and Fpassive. Maximal activation 
at pCa 4.75 was used to determine the maximal Ca
2+
-activated isometric force (Fmax), while 
activations with intermediate [Ca
2+
] (pCa 5.4 – 7.0) yielded the pCa – isometric force 
relationship. Isometric forces at submaximal [Ca
2+
] normalized to Fmax were plotted and then 
fitted to a modified Hill-equation (Origin 6.0, Microcal Software, Northampton, MA. USA). 
The midpoint of the pCa – isometric force relationship defines the Ca2+ sensitivity of the 
contractile machinery (pCa50), while the steepness of the relationship indicates the co-
operativity of the myofilaments (nHill). Experimental procedures were carried out at 15 
o
C to 
maintain the stability of the myocyte-sized preparations. 
2.3.4. Langendorff-perfused hearts 
ORM-3819-evoked changes in the LV contractility were approximated ex vivo by using 
Langendorff-perfused guinea pigs hearts, as detailed elsewhere (Szilagyi et al., 2004). Briefly, 
hearts of the guinea pigs, anesthetized with an intraperitoneal injection of sodium 
pentobarbital (Release, Garbsen, Germany; 150 mg/kg) were quickly excised, rinsed in 
oxygenated perfusion buffer at room temperature and cannulated through the aorta. Modified 
Tyrode-solution used as perfusion buffer containing NaCl (135 mM), MgCl2 (1.0 mM), KCl 
(5.0 mM), CaCl2 (2.0 mM), NaHCO3 (15.0 mM), Na2HPO4 (1.0 mM), glucose (10.0 mM), pH 
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7.3–7.4 (37 Co) was saturated with carbogen (95% O2 and 5% CO2). Every experiment was 
carried out in the presence of constant coronary flow (10.6 ml/min) and constant heart rate 
(280 beats/min). Hence, aortic cannulated and retrograde perfused hearts were suspended in a 
temperature-controlled moist chamber of the Langendorff apparatus (Hugo Sachs Elektronik, 
Germany). After a short period of stabilization (10 min) the left atrium was cannulated 
through the pulmonary vein inserting a latex balloon (size 4) connected to a stainless steel 
cannula and hence to a pressure transducer to determine the isovolumetric LV pressure. The 
volume of the balloon was adjusted to develop a LV diastolic pressure of approximately 5 
mmHg. The pressure signal was then amplified by a two-channel bridge amplifier (Type 301, 
Hugo Sachs Elektronik; Germany) and collected by using the Acquisition v3.1 program 
(Orion Pharma). The cardiac contractility was indexed by determining the magnitude (LV 
systolic pressure) and the positive peak of the first derivative of the LV pressure development 
(+dP/dtmax) (Mason et al., 1971). The hearts were then allowed to stabilize for 30 – 50 min 
before the first data sampling. This approach allowed the characterization the baseline of the 
cardiac contractility regarded as drug free control. Thereafter, ORM-3819 solved in DMSO 
was added to the buffer in the concentration range between 3 nM – 3 µM to determine the 
drug induced changes in the contractile properties of the LV.  
2.3.5. In vivo characterization of the left ventricular contractility 
The in vivo inotropic effect of ORM-3819 was studied in anaesthetized healthy guinea pigs 
and mongrel dogs following the induction of myocardial stunning.  
Guinea-pigs were anesthetized with isoflurane (Forene, Abbott Laboratories, North 
Chicago, IL, USA) and placed on a temperature-controlled pad. Millar catheter pressure 
transducer was inserted into the LV to determine the cardiac contractility indicated by the 
+dP/dtmax. Additionally, the relaxation of the LV was evaluated by measuring the maximal 
rate of the LV pressure decrease (-dP/dtmax). After a stabilization period, incremental 
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intravenous doses of ORM-3819 (0.01 – 3.0 µmol/kg) were injected into the brachial vein. 
Every dose was injected in 30 sec, while the amount of injected fluid was 1 ml/kg. For each 
dose, the maximum effect (one time point) after the bolus injection was used for evaluation. 
In mongrel dogs, myocardial stunning was induced by the occlusion, then reperfusion 
of the anterior descending branch of the left coronary artery (LAD) in the presence of the 
critical constriction of the circumflex branch (LCX) of the same artery. Dogs were 
anaesthetized with sodium-pentobarbitone (Nembutal, Serva, 30 mg/kg intravenously), and 
then artificially ventilated with room air using a variable stroke Harvard ventilator, sufficient 
to maintain blood gases and pH within the normal range (pH: 7.4 ± 0.03; pO2: 87 ± 3.3; pCO2: 
25 ± 2.2). Arterial blood gases were regularly checked with a blood gas analyzer (OP-216, 
Radelkis, Hungary). Polyethylene catheter was introduced into the LV via the left carotid 
artery to measure LV pressure changes in the absence and presence of ORM-3819. The 
+dP/dtmax was measured by means of an electronic differentiator, implicated in the System-6 
apparatus (Triton Technology, San Diego, USA). Segmental shortening was determined to 
assess the regional myocardial contractile performance (Theroux et al., 1974; Szigeti et al., 
2004). Two pairs of piezoelectric crystals were implanted at the level of subendocardium, 
approximately 10 mm apart, in the minor axis of the heart to follow the regional myocardial 
function by sonomicrometry (Triton Technology, San Diego, USA). The crystals were 
inserted into the inner third of the myocardium through small stab wounds, perpendicular to 
the long axis of the ventricle. One pair or crystals were located in the area supplied by the 
LAD and the other in the area supplied by the LCX. Subendocardial segment lengths and the 
LV pressure were recorded simultaneously and analyzed as follows: (a) segment length at 
end-diastole, which was identified as the point just before the onset of the -dP/dtmax; (b) 
segment length at the end-systole defined at the nadir of +dP/dtmax (as the maximum systolic 
excursion occurring at peak +dP/dtmax). The extent of segment shortening was calculated as a 
13 
 
difference in millimetres between the segment length at end-diastole and end-systole and 
expressed as a percentage change (%SS) from the end-diastolic dimensions. After the surgery, 
the animals were allowed to stabilize for 60 min before the commencement of the study 
according to the protocol. Myocardial stunning was induced by a 40 min occlusion and then 
reperfusion of LAD in the presence of the critical constriction of the LCX. After this, both 
arterial bed sides were reperfused. ORM-3819 (1.5 μg/kg/min in six dogs) as well as the 
solvent (0.5 ml per dog/min in seven dogs) were administered intravenously over an 80 min 
period, starting the infusion 30 min after the commencement of the reperfusion. 
2.3.6. Statistical analysis  
Statistical significance was calculated by analysis of variance (ANOVA, repeated measures) 
followed by Dunnet’s two-tailed test and the paired or unpaired Student’s t test. Values are 
given as means ± S.E.M.. Statistical significance was accepted at P < 0.05. Statistical analyses 
were carried out with GraphPad Prism 5.02 software. 
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3. RESULTS 
3.1. Binding of ORM-3819 to cTnC 
ORM-3819 was solved in a buffer solution at pH 6.8 suitable to a protein binding test (0.1 
mM ORM-3819 in 20 mM Bis-Tris, 10 mM CaCl2, 1 mM DTT, pH 6.8) and preliminary 
analysis demonstrated that the samples remained stable over several days (not shown). 
Nevertheless, the solubility of ORM-3819 under our experimental conditions was limited. 
Thus, drug concentrations used in protein binding studies were kept around 0.1 mM. 
The interaction of ORM-3819 with cTnCCS was initially followed by 
1
H-
15
N HSQC 
assays. No resonance doublings were observed in the ORM-3819 titrations, but only chemical 
shift changes were detected, from the 
1
H-
15
N HSQC titration experiments it is clear that 
ORM-3819 interacts with cTnC (Fig. 2A). The interaction of ORM-3819 with cTnCCS 
involved fast kinetics on the NMR timescale with a residence time of < 0.001 sec resulting in 
shift changes of up to 80 Hz without any major line broadening.  
The temperature dependence of cTnCCS – ORM-3819 complex was followed by 1D 
1
H-
13
C HSQC of specifically 
13
C-labelled ORM-3819 and unlabelled cTnCCS. In the presence 
of cTnCCS, the 
1
H resonances of ORM-3819 became broader at lower temperatures, and 
eventually broadened below detection limit, which is an indication of direct interaction of the 
drug with cTnCCS. If cTnCCS was not present, these signals remain sharp at all temperatures 
(Fig. 2B).  
In order to localize the exact binding sites of ORM-3819 in cTnCCS, 2D 
13
C-edited 
1
H-
1
H NOESY spectra of the cTnCCS – ORM-3819 complex were recorded at various 
temperatures (10 – 40 C). However, no specific NOE correlations between ORM-3819 and 
cTnCCS could be observed despite long acquisition times. In fact, due to the low solubility of 
ORM-3819, the spectral quality remained fairly modest and only intra-molecular correlations 
of ORM-3819 were observed (data not shown). 
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3.2. PDE inhibition: the effect of ORM-3819 on the activity of PDE III and PDE IV 
The PDE inhibitory effect of ORM-3819 was tested on purified PDE III and PDE IV 
isozymes (two experimental runs) (Fig. 3). The activity of purified PDE isozymes decreased 
with increasing concentrations of ORM-3819 (1 nM – 10 M). However, ORM-3819 
appeared to be a more potent inhibitor of PDE III than that of PDE IV. Half-maximal 
inhibition (IC50) for PDE III was achieved at a drug concentration of 3.88 ± 0.3 nM, while the 
IC50 for the PDE IV inhibition was 4.95 ± 0.02 µM. Apparently, ORM-3819 did not inhibit 
completely PDE IV even at its 100 μM concentration. The selectivity factor of ORM-3819 for 
the PDE inhibition was  12000. 
3.3. Cardiotonic effects of ORM-3819  
3.3.1. Ca
2+
-sensitizing effects of ORM-3819 in isolated and permeabilized cardiomyocytes 
The Ca
2+
-sensitizing effect of ORM-3819 was demonstrated in isolated and permeabilized 
cardiomyocytes from guinea pig LV. The averages of Fmax and Fpassive under drug-free 
conditions, normalized to the cross-sectional area of the preparations were 19.07 ± 1.6 kN/m
2
 
and 1.08 ± 0.3 kN/m
2
, respectively. These data are comparable to those reported elsewhere 
(Szilagyi et al., 2005). 
 The concentration – response relationship of the Ca2+ sensitization evoked by ORM-
3819 was determined during repeated isometric force measurements at an individual 
submaximal [Ca
2+
] (pCa 5.8) in response to increasing ORM-3819 (10 nM – 100 µM) 
concentrations (Fig. 4A). Of note, the water solubility of ORM-3819 might have limited 
reaching 100 µM concentrations, however, stable and strong biological effects were recorded 
hereby, suggesting that the highest concentration achieved was well above 30 M. We, 
therefore, refer to the 100 M concentration also in this study. Isometric force production 
expressed in absolute terms (kN/m
2
) was augmented in isolated cardiomyocytes significantly 
at 3 μM ORM-3819 concentration and higher (Factive at drug free medium: 3.38 ± 0.32 kN/m
2
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vs. 4.77 ± 0.40 kN/m
2
; P < 0.05), (Fig. 4A). The concentration – response relationship was 
characterized by a half-maximal concentration (EC50) of 2.88 ± 0.14 M and a maximal 
increase in the force production of ~ 101% (n = 10; 5 different animals; Fig. 4B). These data 
were fully comparable to those recorded at a lower submaximal [Ca
2+
] (pCa 6.0) with a half-
maximal Ca
2+
-sensitizing effect of 2.91 ± 0.09 M (n = 10; data not shown). ORM-3819 did 
not affect the Ca
2+
-independent Fpassive production at any applied ORM-3819 concentrations. 
 To obtain more details on the Ca
2+
-sensitizing effect of ORM-3819, isometric force 
production was also assessed at maximal (pCa 4.75) and submaximal [Ca
2+
] (i.e. between pCa 
5.4 – pCa 7.0) in the absence and in the presence ORM-3819, respectively. As illustrated by 
the concentration – response relationship, 10 M, 30 M and 100 M ORM-3819 exerted 
comparable Ca
2+
-sensitizing effects, and therefore10 M test concentration of ORM-3819 
was used to determine the drug evoked changes on the pCa – isometric force relations. ORM-
3819 exposures resulted in a leftward shift on the pCa – isometric force relationship, when 
compared to that of untreated cardiomyocytes (n = 10; 5 different animals, Fig. 4C). ORM-
3819 did not affect the isometric force production either at the maximal (i.e. pCa 4.75) or at 
the lowest (i.e. pCa 7.0) applied [Ca
2+
]. The [Ca
2+
] required to evoke half of the maximal 
force production (i.e. pCa50) reflected the ORM-3819 evoked change in Ca
2+
-sensitivity of 
force production (pCa50 was 5.69 ± 0.01 in the absence and 5.80 ± 0.01 in the presence of 10 
M ORM-3819; ΔpCa50 = 0.11 ± 0.01; P < 0.01; n = 10; 4 different animals, Fig.4D). 
3.3.2. Positive inotropic effect of ORM-3819 in Langendorff-perfused hearts 
The inotropic effect of ORM-3819 was further investigated ex vivo in isolated Langendorff-
perfused guinea pig hearts (n = 5) in a concentration range between 3 nM – 3 μM. LV 
+dP/dtmax was regarded here as an indicator of LV contractile function. ORM-3819 
application increased +dP/dtmax in a concentration-dependent manner (Fig. 5A), proving 
significant at the drug concentration of 10 nM and higher. The maximal ORM-3819 induced 
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increase of +dP/dtmax was ~ 140% relative to the baseline, while the EC50 value of the drug 
effect was 8.9 ± 1.7 nM. Improved cardiac contractility was also reflected by LV systolic 
pressure, reaching significance at 10 nM ORM-3819 concentration and higher (Fig. 5B.).Of 
note, the LV systolic pressure appeared with a similar concentration-dependence for ORM-
3819 (maximal increase, relative to baseline ~ 80%, EC50 = 7.63 ± 1.74 nM) when compared 
to that of changes in the +dP/dtmax. 
3.3.3. In vivo inotropic effects of ORM-3819 in anaesthetized guinea pigs and dogs 
The inotropic effects of ORM-3819 were investigated in vivo first in anaesthetized control 
guinea pigs (n = 6) after intravenous infusions with increasing concentrations of ORM-3819 
(10 nM/kg – 3 M/kg). ORM-3819 improved the contractility of the non-failing myocardium 
indicated by increased +dP/dtmax, proving significant at the application of 0.1 M/kg and 
higher with a corresponding EC50 of 0.13 ± 0.01 M/kg (Fig. 6A.). In addition to the above 
changes of the +dP/dtmax, ORM-3819 treatment resulted in decreased -dP/dtmax (EC50 = 31 ± 
13 nM/kg) suggesting improved relaxation of the LV (Fig 6B). 
 The cardiotonic effect of ORM-3819 was further tested after intravenous 
administration in mongrel dogs following the induction of myocardial stunning, using LAD 
ligation and then release in the presence of simultaneous LCX constriction (n = 6). Basically, 
myocardial stunning was characterized by reduced global and regional contractile function of 
the LV being apparent even in the presence of restored myocardial perfusion. The depressed 
cardiac performance was also present after reperfusion in the animals infused with solvent 
instead of ORM-3819. When ORM-3819 was administered (1.5 μg/kg/min) intravenously for 
80 min after the commencement of the reperfusion, the global myocardial contractile function 
was significantly improved. +dP/dtmax, which was reduced by 33% following the ischaemia-
reperfusion insult was increased again recovering close to the normal level by the end of the 
infusion period (Fig. 7A.), whereas the control solvent was without effect. In line with the 
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above findings, %SS reduced after the ischaemia-reperfusion insult from 24.1 ± 2.1 to 11.0 ± 
2.4 in the ischemic area (supplied by the LAD) which was markedly improved following 
ORM-3819 administration (to 18.8 ± 3) (Fig. 7B). 
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4. DISCUSSION 
This study was carried out to characterize the pharmacological mechanisms underlying the 
positive inotropic effects of ORM-3819. The NMR spectroscopy revealed the binding of 
ORM-3819 to cTnC, resulting in a Ca
2+
 sensitizing effect in isolated and permeabilized 
cardiomyocytes in vitro. ORM-3819 was also reported to evoke a positive inotropic effect in 
Langendorff-perfused hearts ex vivo and in anaesthetized guinea pigs and mongrel dogs with 
myocardial stunning in vivo. The Ca
2+
-sensitization by ORM-3819 was paralleled with a 
highly selective PDE III inhibitory action. 
Levosimendan, an inodilator with structural similarities to ORM-3819 exerts its 
positive inotropic effects primarily through a Ca
2+
-sensitizing mechanism (Papp et al., 2012). 
Previous NMR spectroscopy studies revealed that the Ca
2+
-sensitizing effect is attributable to 
the specific interaction between levosimendan and the Ca
2+
-saturated regulatory domain 
located in the N-terminal region of TnC (Levijoki et al., 2000; Sorsa et al., 2001; Sorsa et al., 
2004). In this study, binding of the novel molecule, ORM-3819 to the Ca
2+
-saturated 
recombinant cTnC was demonstrated similarly to that described previously for levosimendan 
(Sorsa et al., 2001). Our NMR results clearly showed, that ORM-3819 interferes with cTnC, 
manifesting in small chemical shift increases as a function of the amino acid sequence 
determined by 
1
H-
15
N HSQC. Nevertheless, no resonance doublings were observed in the 
ORM-3819 titrations in contrast to that of levosimendan binding (Sorsa et al., 2001), which 
can be potentially attributable to the differences either in the affinity of the two drugs or the 
time scale of the exchange reaction. Further, 1D 
1
H-
13
C HSQC measurements also supported 
the binding of the ORM-3819 to the cTnC by the broadening of the 
1
H resonances of ORM-
3819 in the presence of cTnCCS. Nonetheless, the binding site of ORM-3819 to cTnC could 
not be located by direct NOE distances between the drug and cTnC, which was mainly 
attributable to the low solubility of the drug under protein NMR conditions. Although the 
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magnitude of the TnC-dependent Ca
2+
 sensitization of ORM-3819 was comparable to that of 
levosimendan, ORM-3819 exerted its Ca
2+
-sensitizing effect at higher drug concentrations 
when compared to above drug (EC50:
 
~ 9 nM for levosimendan vs. ~ 3 µM for ORM-3819) 
(Lancaster and Cook, 1997; Szilagyi et al., 2005). Therefore, it is to be acknowledged, that 
although ORM-3819 may sensitize the contractile protein machinery for the activating Ca
2+
 
via binding to TnC, the higher EC50 for the Ca
2+
-sensitizing effect points to a relatively small 
affinity of ORM-3819 for cTnC-binding, when compared to that for levosimendan. These 
data may be potentially in line with the results of the NMR spectroscopy, as well.  
The concentration-dependence for the Ca
2+
-sensitizing effect of ORM-3819 in isolated 
cardiomyocytes clearly did not overlap with that obtained in Langendorff-perfused working 
heart preparations, where the concentration – response relationship for the positive inotropic 
effect of ORM-3819 was positioned leftward from that of Ca
2+
 sensitization. In addition to 
Ca
2+
 sensitization, inhibition of the PDE isozymes represents an alternative mechanism to 
improve the cardiac performance in heart failure (Schmitz et al., 1992). It is achieved by the 
cAMP-dependent increase in the protein kinase A (PKA) activity which, in turn, promotes 
Ca
2+
 entry through sarcolemmal L-type Ca
2+
 channels, triggering Ca
2+
-induced Ca
2+
 release 
from the intracellular Ca
2+
 store, sarcoplasmic reticulum. PKA also increases contractile 
strength by promoting SERCA2b mediated Ca
2+
 uptake into the sarcoplasmic reticulum 
through the phosphorylation of its regulatory protein phospholamban (Ferrier et al., 1998; 
Bangash et al., 2012). In this study, ORM-3819 appeared to be a highly selective PDE III 
inhibitor (IC50 ~ 4 nM) while exerting its PDE IV inhibitor effect only at high concentrations 
(IC50 ~ 5 μM). Based on in vitro assays, we postulate a direct molecular interaction between 
ORM-3819 and PDE III or PDE IV. Structure-to-activity investigations revealed that the 
pyridazinone ring, also present in ORM-3819 is a critical determinant for PDE III inhibition 
with the nitrogen preferably unsubstituted, which interacts directly with the catalytic domain 
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of the PDE III isozyme (Allcock et al., 2011). Previously, several studies were related to the 
inotropic effect of many PDE inhibitors. In isolated guinea pig hearts, the pure PDE III 
inhibitor, milrinone exerted significant positive inotropic effect ex vivo, although the 
magnitude of the evoked changes was lower when compared to that of ORM-3819 in our 
study (Abe et al., 1996; Kaheinen et al., 2004; Zausig et al., 2006). Similarly, the PDE III/IV 
inhibitor enoximone was also demonstrated to evoke a positive inotropic effect in isolated 
guinea pig hearts, however to a lesser extent when compared to levosimendan and than that 
observed in this study for ORM-3819 (Szilagyi et al., 2005; Zausig et al., 2006). These data 
suggest, that ORM-3819 may possess with a dual mechanism of action, at low ORM-3819 
concentrations PDE III inhibition could be dominantly involved in its positive inotropic 
effect, while at higher ORM-3819 concentrations Ca
2+
 sensitization could also contribute. 
Since ORM-3819 is still under early development, neither its pharmacokinetic distribution nor 
its final free plasma concentration reached in therapy is known. For the above reasons, both 
mechanisms are at the moment potentially effective. This dual mechanism of action of ORM-
3819 is in contrast to that for levosimendan, which acts mainly on TnC-dependent Ca
2+
 
sensitization to exert its positive inotropic effect in its therapeutic concentration range (Papp 
et al., 2012). It is to be pointed out that the PDE inhibitory effect of ORM-3819 was highly 
selective for PDE III. This is not the case with most other known PDE III inhibitors (i.e 
enoximone and milrinone), where the selectivity ratio for PDE III vs. PDE IV inhibition is 
significantly lower than that for ORM-3819 (Szilagyi et al., 2005). The above factors may 
explain the missing arryhthmogenic potential of ORM-3819 in dogs undergoing ischaemia 
and reperfusion in contrast to other PDE III inhibitors (Packer et al., 1991). Indeed, the 
pleiotropic effects of ORM-3819 and other less pure Ca
2+
-sensitizating agents (i.e. 
levosimendan) represent a fascinating approach for the treatment of heart failure while 
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avoiding the potential drawbacks of pure Ca
2+
-sensitizers and PDE inhibitors (Pollesello et 
al., 2015). 
Myocardial stunning is a post-ischemic reversible dysfunction of the systolic and 
diastolic performance of the heart, emerging from the ischaemia – reperfusion injury (Camici 
et al., 2008). ORM-3819 was tested and proved to be beneficial in a dog model with 
myocardial stunning evoked by LAD ligation in the presence of LCX constriction, promoting 
the recovery of the depressed global and local myocardial contractile function from the 
ischaemia – reperfusion injury. Since a decrease in the Ca2+ sensitivity of the contractile 
machinery is believed to contribute to the reversible contractile dysfunction after the 
ischaemia – reperfusion injury (Hofmann et al., 1993), it is suggested that improvement of the 
mechanical properties of the stunned myocardium may result from the favourable Ca
2+
-
sensitizing property of ORM-3819 (Soei et al., 1994; Sonntag et al., 2004). Furthermore, PDE 
III inhibitors were also reported to improve the contractile performance of the stunned 
myocardium (Sidi et al., 2007; Shibata et al., 2013). Hence, the dual mechanism of action of 
ORM-3819, involving Ca
2+
 sensitization supported by the selective inhibition of PDE III may 
contribute to the functional recovery following myocardial stunning.  
Of note, changes in intracellular cAMP and protein kinase A dependent protein 
phosphorylation levels upon ORM-3819 administrations have not been addressed here, and 
these can be regarded as potential limitations of our investigations. Furthermore, with regards 
to the anti-stunning effect of levosimendan, the potential effect of ORM-3819 on the opening 
of ATP-dependent potassium channels was not investigated in this study. Other potential 
cardiovascular effects, such as central or peripheral vasodilatation have still to be studied for a 
full characterization of the pharmacological effects of this molecule. Nevertheless, it seemed 
that ORM-3819 infusion did not decrease blood pressure in our dog model with myocardial 
stunning. Therefore, in contrast to levosimendan, ORM-3819 might be used in 
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decompensated heart failure complicated with hypotension, although the vascular effects of 
ORM-3819 should be further elucidated experimentally (McMurray et al., 2012).  
5. CONCLUSION 
Overall, this study characterized the novel chemical entity, ORM-3819 as a potent inotropic 
agent exerting its cardiotonic effect by using a Ca
2+
-sensitizing mechanism further supported 
by the highly selective inhibition of the PDE III isozyme. This dual mechanism of action 
results in the concentration-dependent augmentation of the contractile performance of the 
failing and non-failing myocardium. Based on this recent study, TnC still appears to be 
fascinating for the selection of novel inotropic drug targets, although a safe inotrope needs to 
possess with pleiotropic effects in addition to the Ca
2+
 sensitization to compensate for the 
potential drawbacks of pure Ca
2+
 sensitizers and PDE inhibitors. 
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9. Figure legends 
Fig. 1. The chemical structure of the novel levosimendan-related chemical entity, ORM-3819 
(the (-)-enantiomer of 6-{4-[N’-(4-Hydroxi-3-methoxy-2-nitro-benzylidene)-hydrazino]-
phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one) (A); levosimendan, the (-)-enantiomer of 
{[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono}propanedinitrile) 
(B) and its active metabolite, OR-1896 (the (-)-enantiomer of N-[4-(1,4,5,6-tetrahydro-4-
methyl-6-oxo-3-pyridazinyl)phenyl] acetamide) (C). 
. 
Fig. 2. The interaction of ORM-3819 with cTnCCS was initially followed by 
1
H-
15
N HSQC. 
ORM-3819 binding to Ca
2+
-saturated cTnC gave rise to small chemical shift changes 
presented as a function of amino acid sequence (A). 
1
H-
13
C HSQC of specifically 
13
C-labelled 
ORM-3819 and unlabelled cTnCCS illustrated the broadening of the 
1
H-
13
C signals of ORM-
3819 implying direct interaction of the drug with cTnC. ORM-3819 signal positions are 
indicated by arrows (B). 
 
Fig. 3. The inhibitory potentials of ORM-3819 on PDE III (indicated by solid black lines and 
circles) and PDE IV (indicated by grey lines and circles) isozymes were determined via 
measuring their activities in response to increasing concentration of ORM-3819 (0.1 nM – 
100 µM). Means of two experimental run depicted in a function of the applied ORM-3819 
concentration were fitted to a sigmoid function to evaluate the concentration – response 
relationship of ORM-3819 and determine the drug concentration at that of half-maximal 
effect (IC50). Nevertheless, ORM-3819 did not reach the complete PDE IV inhibition 
potentially due to its scarce solubility. PDE inhibition by milrinone (PDE III) and rolipram 
(PDE IV) are included as reference controls. 
 
Fig. 4. The Ca
2+
-sensitizing effect of ORM-3819 in isolated myocyte-sized preparations of 
guinea pigs LV. Original force records (A) illustrated, that ORM-3819 promoted the isometric 
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force generation at a submaximal [Ca
2+
] in response to that of increasing drug concentrations. 
Cardiomyocyte transfers between relaxing (pCa 9.0) and activating solutions (pCa 4.75 or 
pCa 5.8) were accompanied by brief vertical artefacts. Drug concentrations are depicted under 
the individual force records, while dotted line illustrates the baseline of the isometric force 
production. Length and [Ca
2+
] changes are schematically given above the first activation – 
relaxation cycle. Means of isometric force increases (relative to that of drug free at pCa 5.8) 
were fitted to a concentration – response equation to determine the ORM-3819 concentration 
at its half-maximum effect (EC50) (B). The Ca
2+
-sensitizing effect of ORM-3819 was 
quantified by evaluating pCa – isometric force relationships between pCa 7.0 and pCa 4.75 in 
the absence (black solid lines and circles) and presence of 10 µM ORM-3819 (dark dotted 
lines and open circles). Means of individual isometric force values expressed in normalized 
terms were fitted to a modified Hill-equation. A leftward shift on the pCa – isometric force 
relationships indicates the Ca
2+
 sensitization (C). The Ca
2+
-sensitizing effect of ORM-3819 
was illustrated by the means of the midpoints of the pCa – isometric force relationships 
(pCa50) in the absence and presence of 10 µM ORM-3819 (D). Symbols illustrate means ± 
S.E.M, and asterisks (*) depict significant differences vs. the ORM-3819-free control (P < 
0.05) in all graphs (n = 10 – 10 cardiomyocytes from 4 – 5 different animals). 
 
 
Fig. 5. The concentration-dependent cardiotonic effect of ORM-3819 was investigated in 
Langendorff-perfused guinea pig hearts. Values were expressed in absolute terms (mmHg) in 
the absence (control) and presence of ORM-3819, respectively. The positive inotropic effect 
of ORM-3819 was determined by assessing the drug-induced changes in the derivative of the 
positive peak of LV pressure development (+dP/dtmax) (A) and LV systolic pressure (B). 
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Symbols illustrate means ± S.E.M., and asterisks (*) depict significant differences vs. the 
ORM-3819-free control (P < 0.05) in all graphs (n = 5 isolated heart preparations). 
 
Fig. 6. In vivo investigations for the cardiotonic effect of ORM-3819 were carried out in 
anaesthetized guinea pigs after intravenous administrations of ORM-3819. The positive 
inotropic effect of ORM-3819 was indicated by determining the changes in rate of the LV 
systolic pressure development (+dP/dtmax) (A). Values were expressed in absolute terms 
(mmHg) in the absence (control) and presence of ORM-3819. The effect of ORM-3819 on the 
relaxation of the LV was characterized via determining the maximal rate of the LV systolic 
pressure decrease (-dP/dtmax) (B). Symbols illustrate means ± S.E.M., and asterisks (*) depict 
significant differences vs. the ORM-3819-free control (P<0.05) in all graphs (n = 6 animals). 
 
Fig. 7. In vivo cardiotonic effect of ORM-3819 was also investigated in mongrel dogs with 
myocardial stunning, induced by a 40-min occlusion and then reperfusion of the anterior 
descending branch of the left coronary artery (LAD) in the presence of the critical constriction 
of the circumflex branch (LCX) of the same artery. Both ORM-3819 (solid, dark circles) and 
the solvent (empty circles) were administered intravenously over an 80 min period, starting 
the infusion 30 min after the commencement of the reperfusion. Myocardial stunning was 
characterized by reduced global and regional contractile function of the LV attributable to the 
transient ischaemia – reperfusion insult, even after restoring the myocardial perfusion. 
Infusion of ORM-3819 resulted in improved contractile performance of the myocardium 
indicated by indices of the myocardial contractility, +dP/dtmax (A) and % segmental 
shortening (B) in the presence of ORM-3819 (solid circles) and solvent (empty circles). The 
experimental protocol is depicted above the graphs (n = 6 – 7 animals for each group). 
Symbols illustrate means ± S.E.M., and asterisks (*) depict significant differences between 
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the data obtained after the application of ORM-3819 vs. the respective ORM-3819-free values 
of reperfusion (P < 0.05) in all graphs. 
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